Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | THRB | P10828 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | PHPT1 | Q9NRX4 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | CASP7 | P55210 | 1/20 | 1.00 |
| ▸ | CASP6 | P55212 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.77 |
| ▸ | CASP1 | P29466 | 2/20 | 0.77 |
| ▸ | MED25 | Q71SY5 | 1/20 | 0.77 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.77 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stictic Acid SCHEMBL13495711 | 1.00 | KDM4E (1.00) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15125069 | 0.89 | MEN1 (0.80) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| Norstictic Acid SCHEMBL29369714 | 0.87 | MAPT (1.00) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| Norstictic Acid SCHEMBL13287269 | 0.87 | MAPT (1.00) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15125097 | 0.84 | KDM4E (0.71) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL17049615 | 0.78 | MEN1 (0.68) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL6888417 | 0.77 | MEN1 (0.62) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15581643 | 0.76 | KDM4E (0.66) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15581642 | 0.76 | MAPT (0.85) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| Slazinic Acid SCHEMBL3801772 | 0.76 | MAPT (1.00) | KDM4EMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325548-A1 | TUMOR SUPPRESSOR P73 TRANSCRIPTIONALLY REGULATES C-FLIP TO IMPEDE ITS PRIMING OF EXTRINSIC APOPTOSIS WHILE AN EXAMPLE SWITCHER COMPOUND CB-7587351 DEGRADES C-FLIP PROTEIN | UNIV BROWN (US) | 2025-10-23 | — | — | US | claimed |
| US-20250302863-A1 | USE OF THBS1 INHIBITOR FOR OVERCOMING DRUG RESISTANCE IN CANCER | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-10-02 | — | — | US | claimed |
| WO-2023182846-A1 | USE OF THBS1 INHIBITOR FOR OVERCOMING DRUG RESISTANCE IN CANCER | 한국과학기술원 | 2023-09-28 | — | — | WO | claimed |
| US-20260132142-A1 | EGFR INHIBITOR POLYMORPH FORMS | KATMAI PHARMACEUTICALS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12545686-B2 | Polymorphic forms of (s)-n-(3-bromo-2-fluorophenyl)-7-((4-methylpiperazin-1-yl)methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine as EGFR inhibitors | KATMAI PHARMACEUTICALS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250368695-A1 | Atranorin biosynthesis gene derived from lichens and uses thereof | INDUSTRY ACADEMIC COOPERATION FOUNDATION OF SUNCHON NATIONAL UNIV (KR) | 2025-12-04 | — | — | US | disclosed |
| WO-2025226956-A1 | CATECHOL O-METHYLTRANSFERASE INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250325548-A1 | TUMOR SUPPRESSOR P73 TRANSCRIPTIONALLY REGULATES C-FLIP TO IMPEDE ITS PRIMING OF EXTRINSIC APOPTOSIS WHILE AN EXAMPLE SWITCHER COMPOUND CB-7587351 DEGRADES C-FLIP PROTEIN | UNIV BROWN (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250302863-A1 | USE OF THBS1 INHIBITOR FOR OVERCOMING DRUG RESISTANCE IN CANCER | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-10-02 | — | — | US | disclosed |
| US-20250145634-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-08 | — | — | US | disclosed |
| CN-115215808-B | Compositions and methods for treating cancer | 加利福尼亚大学董事会 | 2025-04-18 | — | — | CN | disclosed |
| CN-111565729-B | Mp53 rescue compounds and methods of treating p53 disease | 上海交通大学医学院附属瑞金医院 | 2023-01-24 | — | — | CN | disclosed |
| WO-2022260402-A1 | ATRANORIN BIOSYNTHESIS GENE DERIVED FROM LICHEN AND USE THEREOF | 순천대학교 산학협력단 | 2022-12-15 | — | — | WO | disclosed |
| CN-115215808-A | Compositions and methods for treating cancer | 加利福尼亚大学董事会 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022219128-A1 | IN VITRO TESTS ALLOWING TO IDENTIFY THE POTENTIAL FOR MDM2 INHIBITORS TO INDUCE THE SELECTION OF MUTATIONS IN PATIENTS SUFFERING FROM A MYELOPROLIFERATIVE NEOPLASM | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-10-20 | — | — | WO | disclosed |
| WO-2021232015-A9 | PLATELET DERIVED EXTRACELLULAR VESICLES | CELLPHIRE, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022174234-A2 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-11377451-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2022061201-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145634-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | KDM4E 3386/4885MEN1 3431/4885ALDH1A1 2784/4885 |
| US-11377451-B2 | Compositions and methods for treating cancer | TP53, EGFR, SLC2A1 | KDM4E 3091/4885MEN1 3595/4885ALDH1A1 2649/4885 |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | KDM4E 3386/4885MEN1 3431/4885ALDH1A1 2784/4885 |
| US-12545686-B2 | Polymorphic forms of (s)-n-(3-bromo-2-fluorophenyl)-7-((4-methylpiperazin-1-yl)methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine as EGFR inhibitors | ERBB2, CYP1B1, EGFR | KDM4E 2915/4885MEN1 3269/4885ALDH1A1 2721/4885 |
| US-20250325548-A1 | TUMOR SUPPRESSOR P73 TRANSCRIPTIONALLY REGULATES C-FLIP TO IMPEDE ITS PRIMING OF EXTRINSIC APOPTOSIS WHILE AN EXAMPLE SWITCHER COMPOUND CB-7587351 DEGRADES C-FLIP PROTEIN | BCOR, CCAR2, CEBPZ | KDM4E 967/4885MEN1 3174/4885ALDH1A1 3993/4885 |
| US-20260132142-A1 | EGFR INHIBITOR POLYMORPH FORMS | EGFR, ERBB2, ERBB4 | KDM4E 2558/4885MEN1 2346/4885ALDH1A1 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.